Emergent BioSolutions | EBS - 营业费用



金融业
股票价格
USD
资产
USD 1.82B
现金及等价物
USD 111.7M
销售成本
USD 381.2M
流动资产
USD 679.5M
流动负债
USD 651.3M
债务
USD 903.2M
股息收益率
0
EBIT
USD -148.1M
EBITDA
USD -113.5M
员工
1.6K
EPS每股收益
USD -0.77
股本和储备
USD 649.3M
销售毛利
USD 10M
债务利息支出
USD 17.9M
贷款资金
USD 446.5M
市值
USD 404.6M
净收入
USD -261.3M
营业费用
USD 555.9M
营业利润
USD -218M
普通股股本
USD 100K
PE价格收益
14.4
税前利润
USD -130.8M
销售收入
USD 276.6M
销售和管理费用
USD 182.8M
股票
USD 328.9M
贸易债权人
USD 112.2M
应收帐款人
USD 290.1M


营业费用 更改 日
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
ALKERMES USD 1.75B 1.43B 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amarin USD 51.48M 113K 2025-12
ANI Pharmaceuticals USD 562.3M 344.37M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Coherus Biosciences USD 51.83M 2.48M 2025-12
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Exelixis USD 359.47M 3.28M 2026-03
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 364M 54M 2026-03
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
Lonza CHF 2.9B 184M 2025-06
Merck USD 18.17B 8.01B 2026-03
Moderna USD 1.78B 242M 2026-03
Myriad Genetics USD 212.8M 16.2M 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Pacira USD 172.75M 20.93M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Sanofi EUR 9.31B 1.2B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
United Therapeutics USD 5.9B 5.1B 2026-03
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12
Xoma USD 22.84M 1.67M 2024-09